2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 33

B Cell Abnormalities in Patients with Chronic Cutaneous Lupus Erythematosus
Abstract Number: 2974

B Cell Binding Autoreactive VH4.34 Antibodies Are Specific to Lupus, Consist of Diverse Isotypes, and Are Associated with High Disease Activity and Lupus Nephritis
Abstract Number: 836

B Cell Receptor Sequencing of Anti-Citrullinated Protein Antibody Expressing B Cells Indicates a Selective Advantage for the Introduction of N-Glycosylation Sites during Somatic Hypermutation
Abstract Number: 898

B Cell Specific TLR9 Suppresses Disease in Murine Lupus
Abstract Number: 807

B Cells in Giant Cell Arteritis: a Novel Target for Treatment?
Abstract Number: 40

B-Cell Attracting Chemokine-1 (BCA-1) and Macrophage Inflammatory Protein-3 Alpha (MIP-3α) Act Synergistically in the Recruitment of B Cells in the Rheumatoid Synovium
Abstract Number: 2936

B-Cell Depletion By Rituximab Affects the Distribution of Effector Th-Cell Subsets in Patients with ANCA Associated Vasculitis
Abstract Number: 35

B-Cell Subset Differences in Inflammatory Rheumatic Diseases
Abstract Number: 56

Baicalein, a Plant-Derived Small Molecule, Activate Nrf2/Autophagy Signaling Axis Via MEK1/2-ERK1/2-Elk1 Pathway to Suppress the Expression of IL-6 in Human Osteoarthritis Chondrocytes
Abstract Number: 415

Baricitinib Reduces GlycA Levels in Phase 2 and Phase 3 Clinical Trials in Patients with Moderate to Severe Rheumatoid Arthritis
Abstract Number: 2316

Barriers at School for Children with Juvenile Idiopathic Arthritis (JIA) – a Patient Reported Outcome
Abstract Number: 225

Barriers to the Use of Methotrexate in Ethiopia: Survey of Pharmacy Providers
Abstract Number: 2002

Baseline 18F Sodium Fluoride Uptake of Vertebral Bodies but Not Vertebral Corners on Positron Emission Tomography Is Associated with Changes in Bone Mineral Density at Lumbar Vertebrae in Ankylosing Spondylitis: A 1-Year Longitudinal Study
Abstract Number: 436

Baseline Anemia As a Predictor of Radiographic Progression in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analyses from Two Phase 3 Trials
Abstract Number: 1695

Baseline Characteristics and Outcomes in a Retrospective Cohort of Patients with Systemic Sclerosis Related Interstitial Lung Disease
Abstract Number: 134

Baseline Characteristics and Rates of Hospitalized Infections in Patients with Rheumatoid Arthritis Treated with Non-TNF Inhibitors in Denmark and Sweden
Abstract Number: 2593

Baseline Characteristics of Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab
Abstract Number: 2526

Baseline Data from the Recent-Onset Psoriatic Arthritis Registry of the Spanish Society of Rheumatology
Abstract Number: 2434

Baseline Expressions of Cellular microRNA-31 and microRNA-10a Predict Remission and Low Disease Activity in Patients with Early Rheumatoid Arthritis after Six and Twelve Months of Therapy
Abstract Number: 672

Baseline Hyperuricemia As a Predictive Value for Development of Lupus Nephritis in Premenopausal SLE Patients
Abstract Number: 2201

Baseline Periarticular Tibial Knee Bone Mineral Density Is Associated with Change in Static Alignment
Abstract Number: 610

Baseline Structural Damage Predicts Response to Abatacept in Patients with Psoriatic Arthritis: A Post Hoc Analysis from a Phase III Study
Abstract Number: 868

Baseline Troponin Levels Are Associated with Mortality in a Cohort of Patients with Inflammatory Polyarthritis: Results from the Norfolk Arthritis Register
Abstract Number: 412

Baseline Values for Plantar Pressure and Background Characteristics As Indicators for the Limit of Conservative Treatment of Rheumatoid Forefoot Deformity
Abstract Number: 465

Basement Membrane Remodeling in Rheumatoid Arthritis Associates with Disease Activity, Response to IL-6 Inhibitor Treatment and Radiographic Progression: Analysis of Two Phase III Clinical Trials
Abstract Number: 2720

Behcet’s Disease in Southeastern Michigan: A Single Center Comparative Study
Abstract Number: 540

Being Elderly Is Not a Predictive Factor of Discontinuation of Abatacept Due to Adverse Events in Rheumatoid Arthritis Patients with Concomitant Methotrexate: A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study
Abstract Number: 1400

Beneficial Effect of Anti-IL-6 Blockade on Insulin Resistance and Insulin Sensitivity in Patients with Rheumatoid Arthritis
Abstract Number: 1796

Benefits and Sustainability of a Learning Collaborative for Implementation of Treat to Target in Rheumatoid Arthritis: Results of Phase II of a Cluster Randomized Controlled Trial
Abstract Number: 45

BIIB063, a Potent Anti-CD40 Antagonistic Monoclonal Antibody (MAb): Lessons Learned from an Early Development Program.
Abstract Number: 299

Bik Plays an Important Role of Cell Proliferation Caused By Nitric Oxide in Rheumatoid Arthritis Synovium
Abstract Number: 2397

Bilateral Femoral DXA Scan in Patients with Rheumatoid Arthritis
Abstract Number: 1936

Bimekizumab Blocks T Cell-Mediated Osteogenic Differentiation of Periosteal Stem Cells: Coupling Pathological Bone Formation to IL-17A and IL-17F Signaling
Abstract Number: 1571

Bimekizumab Dual Inhibition of IL-17A and IL-17F Provides Evidence of IL-17F Contribution to Chronic Inflammation in Disease-Relevant Cells
Abstract Number: 307

Biochemical Intervertebral Disc Alterations in Patients with Low Back Pain and Radiculopathy
Abstract Number: 922

Biologic DMARD Prescribing Patterns in Elderly Patients with Rheumatoid Arthritis
Abstract Number: 2278

Biologic Switching Among JIA Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry
Abstract Number: 1046

Biological and Targeted Synthetic Dmards’ Prior Authorization Time Is Significantly Reduced with Pharmacy Presence in the Rheumatology Clinic
Abstract Number: 1562

Biological DMARD Efficacy in Psoriatic Arthritis: A Systematic Review and Meta-Analysis on ACR Response Criteria, PASI Response Criteria, HAQ-DI, Enthesitis and Dactylitis Outcomes
Abstract Number: 2405

Biological Function Integrated Prediction of Severe Radiographic Progression in Rheumatoid Arthritis: A Nested Case Control Study
Abstract Number: 2332

Biomarkers for the Diagnosis and the Identification of Risk of Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA)
Abstract Number: 1211

Biomarkers Predictive of Pain Improvement in Knee Osteoarthritis Subjects Treated with the Anti-IL-1α/β Dual Variable Domain Immunoglobulin ABT-981
Abstract Number: 572

Biopsy Accuracy in Sjögren’s Syndrome: Analysis of 803 Patients Presenting with Sicca Syndrome Referred to Labial Salivary Gland Biopsy
Abstract Number: 226

Biopsy Proven Giant Cell Arteritis in African Descent Populations: Incidence and Characteristics in Martinique, French West Indies
Abstract Number: 2442

Biosimilar Candidate BI 695501 and Adalimumab Reference Product Have Similar Efficacy and Safety in Patients with Moderately-to-Severely Active Rheumatoid Arthritis (RA): 1-Year Results from a Phase III Study
Abstract Number: 1037

Biosimilar Knowledge Among US Rheumatologists – a Survey
Abstract Number: 2287

Biosimilar Use in Children and Young People with Juvenile Idiopathic Arthritis in a Real-World Setting in the United Kingdom
Abstract Number: 2495

Biosimilarity between Humira® and the Biosimilar Candidate SB5 in Product Quality
Abstract Number: 1036

Blood Glucose Changes Surrounding Initiation of Tumor-Necrosis Factor Inhibitors and Conventional Disease-Modifying Anti-Rheumatic Drugs in Veterans with Rheumatoid Arthritis
Abstract Number: 2110

Blood Group ”a“ Was Increased in FMF Patients and Blood Group ”0“ May be Associated with Colchicine Resistance
Abstract Number: 1918

Blood Levels of Complement Split Product iC3b and C3 Outperform Traditional Biochemical Measures of SLE Disease Activity in Associating with Active and Clinically Meaningful Changes
Abstract Number: 1267

Blood Pressure Control over Time in Childhood-Onset Systemic Lupus Erythematous
Abstract Number: 503

BMS-986195 Is a Highly Selective and Rapidly Acting Covalent Inhibitor of Bruton’s Tyrosine Kinase with Robust Efficacy at Low Doses in Preclinical Models of RA and Lupus Nephritis
Abstract Number: 514

BMS-986195, a Novel, Rapidly Acting, Covalent Inhibitor of Bruton’s Tyrosine Kinase: Safety, Pharmacokinetic and Pharmacodynamic Profiles in Healthy Participants
Abstract Number: 2961

Body Composition and Myokine Levels in Juvenile Dermatomyositis and Associations with Physical Function
Abstract Number: 1634

Body Mass Index and Disease Activity in Systemic Lupus Erythematosus- a Paradoxical Relationship?
Abstract Number: 2378

Body Mass Index and Persistence of Conventional Dmards and TNF Inhibitors in Rheumatoid Arthritis
Abstract Number: 1636

Body Mass Index at Disease Onset Is Predictive of Future Organ Damage in Systemic Lupus Erythematosus
Abstract Number: 1472

Body Mass Index Does Not Affect Response to Rituximab in Patients with Rheumatoid Arthritis: Results from Turkbio Registry
Abstract Number: 609

Body Mass Index Does Not Influence the Efficacy of Subcutaneous Abatacept in Patients with Psa: Results from a Phase III Trial
Abstract Number: 1830

Bone Marrow Edema in Sacroiliac Joints of Young Athletes Is Common and Shows Most Frequently in the Posterior Lower Ilium
Abstract Number: 1224

BONE Metabolism in LIVER Transplant Patients Two-Year Study. Influence of Medical Intervention PRIOR to Surgery and Antiresorptive Treatment
Abstract Number: 1225

BONE Mineral Density and Vertebral Fractures in Gaucher Disease Patients Treated with Imiglucerase
Abstract Number: 22

Bone Regulatory Cytokine Production By B Cells in Rheumatoid Arthritis Is Dependent on NF-κb Activation and Autophagy Pathways
Abstract Number: 1183

Bone Sarcoidosis: A Multicenter Study
Abstract Number: 1594

Bone Turnover Markers in Adults with Systemic Lupus Erythematosus
Abstract Number: 2671

Bosentan in Scleroderma Renal Crisis: A National Open Label Prospective Study
Abstract Number: 2319

Bradycardia after High-Dose Solu-Medrol
Abstract Number: 2753

Brain Functional Connectivity Features of Pain Centralisation Relate to Degree of ‘Fibromyalgianess’ in Rheumatoid Arthritis
Abstract Number: 1735

Brain Infiltrating CD4 T Cells Have a Pathogenic T Follicular Helper-like Phenotype in Neuropsychiatric Lupus
Abstract Number: 1912

Broad Immunophenotyping Results: CCR10 Expressing CD8 T Cells Distinguish Psoriatic Arthritis from Psoriasis Limited to Skin Involvement
Abstract Number: 29

BTK Inhibition Ameliorates Lupus-Associated Neuropsychiatric and Skin Disease
Abstract Number: 2561

BTK Inhibition Ameliorates Renal Disease in Spontaneous Murine Lupus Nephritis
Abstract Number: 1057

Budgetary Impact Analysis of Real-World Dosing Patterns in Matched Cohorts of Rheumatoid Arthritis Patients Treated with Infliximab or Golimumab Intravenous Anti-TNF Medications
Abstract Number: 3

Burden of Antiphospholipid Syndrome in a Thromboembolic Disease Registry
Abstract Number: 1033

Burden of Illness in Patients with RA and Anti-Cyclic Citrullinated Peptide Positivity
Abstract Number: 1958

Burden of Rheumatic Disease Among Korean Women in Childbearing Years Based on the National Health Insurance Service-National Sample Cohort

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].